Not Yet RecruitingNot Applicable

PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study

United States60 participantsStarted 2026-12

Plain-language summary

This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients ≥18 years with a history of cancer.
✓. Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
✓. Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
✓. Ability to understand a written informed consent form, and willing to sign it prior to study registration.

Exclusion criteria

✕. Patient \<18 years.
✕. Without a personal history of cancer.
✕. Existing cardiomyopathy diagnosed after cancer diagnosis.
✕. Documented cognitive impairment.
✕. Patient or patient representative who is unable and unwilling to sign the informed consent form.

What they're measuring

Medication use

Timeframe: Week 0

Medication use

Timeframe: Week 12

Medication use

Timeframe: Week 24

Imaging surveillance

Timeframe: Week 0

Imaging surveillance

Timeframe: Week 12

Imaging surveillance

Timeframe: Week 24

Trial details

NCT IDNCT05377320

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12

Contact for this trial

Yee Chung Cheng, MD

414-805-4600 ycheng@mcw.edu

View on ClinicalTrials.gov More Heart Failure trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients ≥18 years with a history of cancer.
✓. Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
✓. Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
✓. Ability to understand a written informed consent form, and willing to sign it prior to study registration.

Exclusion criteria

✕. Patient \<18 years.
✕. Without a personal history of cancer.
✕. Existing cardiomyopathy diagnosed after cancer diagnosis.
✕. Documented cognitive impairment.
✕. Patient or patient representative who is unable and unwilling to sign the informed consent form.